PT - JOURNAL ARTICLE AU - Meemansa Sood AU - Ulrike Suenkel AU - Anna-Katharina von Thaler AU - Helena U. Zacharias AU - Kathrin Brockmann AU - Gerhard W. Eschweiler AU - Walter Maetzler AU - Daniela Berg AU - Holger Fröhlich AU - Sebastian Heinzel TI - Bayesian network modeling of risk and prodromal markers of Parkinson’s disease AID - 10.1101/2022.05.18.22275239 DP - 2022 Jan 01 TA - medRxiv PG - 2022.05.18.22275239 4099 - http://medrxiv.org/content/early/2022/05/21/2022.05.18.22275239.short 4100 - http://medrxiv.org/content/early/2022/05/21/2022.05.18.22275239.full AB - Parkinson’s disease (PD) is characterized by a long prodromal phase with a multitude of markers indicating an increased PD risk prior to clinical diagnosis based on motor symptoms. Current PD prediction models do not consider interdependencies of single predictors, lack differentiation by subtypes of prodromal PD, and may be limited and potentially biased by confounding factors, unspecific assessment methods and restricted access to comprehensive marker data of prospective cohorts.We used prospective data of 20 established risk and prodromal markers of PD in 1178 healthy, PD-free individuals and 24 incident PD cases collected longitudinally in the Tübingen evaluation of Risk factors for Early detection of NeuroDegeneration (TREND) study at 4 visits over up to 10 years. We employed artificial intelligence (AI) to learn and quantify PD marker interdependencies via a Bayesian network (BN) with uncertainty estimation using bootstrapping. The BN was employed to generate a synthetic cohort and individual marker profiles.Robust interdependencies were observed for BN edges from age to subthreshold parkinsonism and urinary dysfunction, sex to substantia nigra hyperechogenicity, depression, non-smoking and to constipation; depression to symptomatic hypotension and excessive daytime somnolence; solvent exposure to cognitive deficits and to physical inactivity; and non-smoking to physical inactivity. Conversion to PD was interdependent with prior subthreshold parkinsonism, sex and substantia nigra hyperechogenicity. Several additional interdependencies with higher statistical uncertainty were identified. Synthetic subjects generated via the BN based representation of the TREND study were realistic as assessed through multiple comparison approaches of real and synthetic data.Altogether our work demonstrates the potential of modern AI approaches (specifically BNs) in two ways: First, to model and understand interdependencies between PD risk and prodromal markers, which are so far not accounted for in PD prediction models. Second, the generative nature of BNs opens the door for facilitating data sharing in a legally compliant and privacy preserving manner.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe TREND study is being conducted at the University Hospital Tuebingen and has been supported by the Hertie Institute for Clinical Brain Research, the DZNE, the Geriatric Center of Tuebingen, the Center for Integrative Neuroscience, Teva Pharmaceutical Industries, Union Chimique Belge, Janssen Pharmaceuticals, the International Parkinson Foundation and the German Research Society (DFG). The supporting institutions had no influence on the design, conduct, or analysis of the study. This work was (partially) funded by DIGIPD (01KU2110), a project supported by the Federal Ministry of Science and Education (BMBF), under the frame of ERA PerMed.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee of the Medical Faculty of the University of Tuebingen, Germany, gave ethical approval for this work (444/2019BO2).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors